<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of microbiology, epidemiology and immunobiology</journal-id><journal-title-group><journal-title xml:lang="en">Journal of microbiology, epidemiology and immunobiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Журнал микробиологии, эпидемиологии и иммунобиологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0372-9311</issn><issn publication-format="electronic">2686-7613</issn><publisher><publisher-name xml:lang="en">Central Research Institute for Epidemiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1324</article-id><article-id pub-id-type="doi">10.36233/0372-9311-350</article-id><article-id pub-id-type="edn">qdaaci</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL RESEARCHES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Influence of povidone-yodine on the sensitivity of clinical isolates of <italic>Klebsiella pneumoniae</italic> to antibiotics</article-title><trans-title-group xml:lang="ru"><trans-title>Влияние повидон-йода на чувствительность клинических изолятов <italic>Klebsiella pneumoniae</italic> к антибиотикам</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2095-2378</contrib-id><contrib-id contrib-id-type="spin">2944-9248</contrib-id><name-alternatives><name xml:lang="en"><surname>Tsyrkunova</surname><given-names>Zhanna F.</given-names></name><name xml:lang="ru"><surname>Циркунова</surname><given-names>Жанна Федоровна</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p>Cand. Sci. (Biol.), Head, Laboratory of nosocomial infections</p></bio><bio xml:lang="ru"><p>к.б.н., зав. лаб. внутрибольничных инфекций научно-исследовательской части</p></bio><email>tsyrkunova@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8354-6380</contrib-id><name-alternatives><name xml:lang="en"><surname>Emelyanova</surname><given-names>Alesya A.</given-names></name><name xml:lang="ru"><surname>Емельянова</surname><given-names>Алеся Александровна</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p>junior researcher, Laboratory of nosocomial infections</p></bio><bio xml:lang="ru"><p>м.н.с. лаб. внутрибольничных инфекций научно-исследовательской части</p></bio><email>tsyrkunova@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4818-289X</contrib-id><name-alternatives><name xml:lang="en"><surname>Gudkova</surname><given-names>Elena I.</given-names></name><name xml:lang="ru"><surname>Гудкова</surname><given-names>Елена Ивановна</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Associate Professor, Head, Research unit</p></bio><bio xml:lang="ru"><p>к.м.н., доцент, руководитель научно-исследовательской части</p></bio><email>tsyrkunova@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7896-1413</contrib-id><name-alternatives><name xml:lang="en"><surname>Skorokhod</surname><given-names>Gennady A.</given-names></name><name xml:lang="ru"><surname>Скороход</surname><given-names>Геннадий Алексеевич</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Associate Professor, leading researcher, Laboratory of nosocomial infections</p></bio><bio xml:lang="ru"><p>к.м.н., доцент, ведущий сотрудник лаб. внутрибольничных инфекций научно-исследовательской части</p></bio><email>tsyrkunova@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Belarusian State Medical University</institution></aff><aff><institution xml:lang="ru">Белорусский государственный медицинский университет</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-05-22" publication-format="electronic"><day>22</day><month>05</month><year>2023</year></pub-date><volume>100</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>209</fpage><lpage>218</lpage><history><date date-type="received" iso-8601-date="2022-10-26"><day>26</day><month>10</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Tsyrkunova Z.F., Emelyanova A.A., Gudkova E.I., Skorokhod G.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Циркунова Ж.Ф., Емельянова А.А., Гудкова Е.И., Скороход Г.А.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Tsyrkunova Z.F., Emelyanova A.A., Gudkova E.I., Skorokhod G.A.</copyright-holder><copyright-holder xml:lang="ru">Циркунова Ж.Ф., Емельянова А.А., Гудкова Е.И., Скороход Г.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://microbiol.crie.ru/jour/article/view/1324">https://microbiol.crie.ru/jour/article/view/1324</self-uri><abstract xml:lang="en"><p><bold>Introduction. </bold>Cross-resistance of microorganisms to antibiotics against the background of the use of biocides in subinhibitory concentrations is an urgent problem of modern health care.</p> <p><bold>The aim </bold>of the work is to study the effect of povidone-iodine on the sensitivity of clinical isolates of <italic>Klebsiella pneumoniae</italic> to antibiotics.</p> <p><bold>Materials and methods. </bold>The work analyzed the effect of povidone-iodine at subinhibitory concentrations on changes in the sensitivity of clinical isolates of <italic>K. pneumoniae</italic> (<italic>n</italic> = 9) to antibacterial agents (<italic>n</italic> = 15). Adaptation of bacteria to povidone-iodine was carried out using periodic cultivation of microorganisms, which was carried out in 96-well culture plates for suspension cultures (non-treated) without stirring. The sensitivity of bacteria to antibiotics was assessed using an automatic analyzer “Vitek2Compact” (“BioMerieux”) using AST-204 charts.</p> <p><bold>Results. </bold>During the adaptation of clinical isolates of <italic>K. pneumoniae</italic> to povidone-iodine, an increase in the sensitivity of bacteria to antibiotics was shown. The minimum inhibitory concentrations (MIC) of 11 antibacterial agents in relation to the studied cultures decreased by an average of 2.35–23.2 times compared with the control values. Under the experimental conditions, the sensitivity of the studied cultures increased to amoxicillin/clavulanic acid by ≥ 2 – ≥ 8 times, piperacillin/tazobactam — by ≥ 2 – ≥ 32 times, ceftazidime — by 4 – ≥ 16 times, ami-kacin — 2 – ≥ 16 times, ertapenem — 2.0–8.0 times, meropinem — 2–8 times, cefepim — ≥ 4 – ≥ 64 times, ciprofloxacin — 4 – ≥ 16 times, gentamicin — 2 – ≥ 8 times, norfloxacin — 2–8 times, nitrofurantoin — 2–4 times. An increase in the level of sensitivity to antibiotics was found in 50–100% of the studied clinical bacterial isolates. A similar effect has not been established for ampicillin, cefotaxime, imipenem, and trimethoprim/sulfamethoxazole. It should be noted that under the conditions of the experiment, intraspecific heterogeneity of clinical isolates of <italic>K. pneumoniae</italic> was revealed in terms of the level of acquired sensitivity to antibacterial agents.</p> <p><bold>D</bold><bold>iscussion. </bold>Our results are not described in the scientific literature and require further study and explanation.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение. </bold>Развитие устойчивости микроорганизмов к антибиотикам на фоне использования биоцидов в субингибирующих концентрациях является актуальной проблемой современного здравоохранения.</p> <p><bold>Цель </bold>работы — изучить влияние повидон-йода на чувствительность клинических изолятов <italic>Klebsiella pneumoniae</italic> к антибиотикам.</p> <p><bold>Материалы и методы. </bold>В работе проанализировано влияние повидон-йода в субингибирующих концентрациях на изменение чувствительности клинических изолятов <italic>K. pneumoniae </italic>(<italic>n</italic> = 9) к антибактериальным средствам (<italic>n</italic> = 15). Адаптацию бактерий к повидон-йоду проводили с использованием периодического культивирования микроорганизмов, которое осуществляли в 96-луночных культуральных планшетах для суспензионных культур (non-treated) без перемешивания. Оценку чувствительности бактерий к антибиотикам проводили с помощью автоматического анализатора «Vitek2Compact» («BioMerieux») с использованием карт AST-204.</p> <p><bold>Результаты. </bold>В ходе адаптации клинических изолятов <italic>K. pneumoniae</italic> к повидон-йоду показано увеличение чувствительности бактерий к антибиотикам. Минимальные ингибирующие концентрации 11 антибактериальных средств в отношении изученных культур снизились в среднем в 2,35–23,2 раза по сравнению с контрольными значениями. В условиях опыта чувствительность изученных культур возросла к амоксициллин/клавулановой кислоте в ≥ 2 – ≥ 8 раз, пиперациллин/тазобактаму — в ≥ 2 – ≥ 32 раза, цефтазидиму — 4 – ≥ 16 раз, амикацину — в 2 – ≥ 16 раз, эртапенему — в 2–8 раз, меропинему — в 2–8 раз, цефепиму — ≥ 4– ≥ 64 раз, ципрофлоксацину — в 4 – ≥ 16 раз, гентамицину — в 2 – ≥ 8 раз, норфлоксацину — в 2–8 раз, нитрофурантоину — в 2–4 раза. Повышение уровня чувствительности к антибиотикам выявлено у 50–100% изученных клинических изолятов бактерий. Подобный эффект не был установлен для ампициллина, цефотаксима, имипенема и триметоприм/сульфаметоксазола. В условиях опыта была выявлена внутривидовая гетерогенность клинических изолятов <italic>K. pneumoniae</italic> по уровню приобретённой чувствительности к антибактериальным средствам.</p> <p><bold>Обсуждение. </bold>Полученные нами результаты не описаны в научной литературе и требуют дальнейшего изучения и объяснения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>antiseptics</kwd><kwd>povidone-iodine</kwd><kwd>betadine</kwd><kwd>antibiotics</kwd><kwd>sensitivity</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>антисептики</kwd><kwd>повидон-йод</kwd><kwd>бетадин</kwd><kwd>антибиотики</kwd><kwd>чувствительность</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Министерство здравоохранения Республики Беларусь</institution></institution-wrap><institution-wrap><institution xml:lang="en">Ministry of Health of the Republic of Belarus</institution></institution-wrap></funding-source><award-id>3.11</award-id></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Le T., Wang L., Zeng C., et al. Clinical and microbiological characteristics of nosocomial, healthcare-associated, and community-acquired Klebsiella pneumoniae infections in Guangzhou, China. Antimicrob. Resist. Infect. Control, 2021;10(1):41. DOI: https://doi.org/10.1186/s13756-021-00910-1</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Zhang H., Guo Z., Chai Y., et al. Risk factors for and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae nosocomial infections: a retrospective study in a tertiary hospital in Beijing, China. Infect. Drug. Resist. 2021;14:1393–401. DOI: https://doi.org/10.2147/IDR.S298530</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Durdu B., Hakyemez I.N., Bolukcu S., et al. Mortality markers in nosocomial Klebsiella pneumoniae bloodstream infection. Springerplus. 2016;5(1):1892. DOI: https://doi.org/10.1186/s40064-016-3580-8</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Frasera J.L., Mwatondo A., Alimi Y.H., et al. Healthcare-associated outbreaks of bacterial infections in Africa, 2009–2018: A review. Int. J. Infect. Dis. 2021;103:469–77. DOI: https://doi.org/10.1016/j.ijid.2020.12.030</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Molton J.S., Tambyah P.A., Ang B.S., et al. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. Clin. Infect. Dis. 2013;56(9):1310–8. DOI: https://doi.org/10.1093/cid/cit020</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Avershina E., Shapovalova V., Shipulin G. Fighting antibiotic resistance in hospital-acquired infections: current state and emerging technologies in disease prevention, diagnostics and therapy. review article. Front. Microbiol. 2021;12:707330. DOI: https://doi.org/10.3389/fmicb.2021.707330</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Cassini A., Hogberg L.D., Plachouras D., et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect. Dis. 2019;19(1):56–66. DOI: https://doi.org/10.1016/S1473-3099(18)30605-4</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Ahmad M., Khan A.U. Global economic impact of antibiotic resistance: A review. J. Glob. Antimicrob. Resist. 2019;19:313–6. DOI: https://doi.org/10.1016/j.jgar.2019.05.024</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Singer A.C., Shaw H., Rhodes V., Hart A. Review of antimicrobial resistance in the environment and its relevance to environmental regulators. Front. Microbiol. 2016;7:1728. DOI: https://doi.org/10.3389/fmicb.2016.01728</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Zhang M., Wan K., Zeng J., et al. Co-selection and stability of bacterial antibiotic resistance by arsenic pollution accidents in source water. Environ. Int. 2020;135:105351. DOI: https://doi.org/10.1016/j.envint.2019.105351</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Zhang Y., Gu A.Z., Cen T., et al. Sub-inhibitory concentrations of heavy metals facilitate the horizontal transfer of plasmid-mediated antibiotic resistance genes in water environment. Environ. Pollut. 2018;237:74–82. DOI: https://doi.org/10.1016/j.envpol.2018.01.032</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kampf G. Biocidal agents used for disinfection can enhance antibiotic resistance in gram-negative species. Antibiotics (Basel). 2018;7(4):110. DOI: https://doi.org/10.3390/antibiotics7040110</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Wand M.E., Bock L.J., Bonney L.C., Sutton J.M. Mechanisms of increased resistance to chlorhexidine and cross-resistance to colistin following exposure of Klebsiella pneumoniae clinical isolates to chlorhexidine. Antimicrob. Agents Chemother. 2016; 61(1):e01162-16. DOI: https://doi.org/10.1128/AAC.01162-16</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Eggers M. Infectious disease management and control with povidone iodine. Infect. Dis. Ther. 2019;8(4):581–93. DOI: https://doi.org/10.1007/s40121-019-00260-x</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Kramer A., Dissemond J., Kim S., et al. Consensus on wound antisepsis: update 2018. Skin Pharmacol. Physiol. 2018; 31(1): 28–58. DOI: https://doi.org/10.1159/000481545</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Grzybowski A., Kanclerz P., Myers W.G. The use of povidone-iodine in ophthalmology. Curr. Opin. Ophthalmol. 2018;29(1): 19–32. DOI: https://doi.org/10.1097/ICU.0000000000000437</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Williamson D.A., Carter G.P., Howden B.P. Current and emerging topical antibacterials and antiseptics: agents, action, and resistance patterns. Clin. Microbiol. Rev. 2017;30(3):827–60. DOI: https://doi.org/10.1128/CMR.00112-16</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Barreto R., Barrois B., Lambert J., et al. Addressing the challenges in antisepsis: focus on povidone iodine. Int. J. Antimicrob. Agents. 2020;56(3):106064. DOI: https://doi.org/10.1016/j.ijantimicag.2020.106064</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Merchel Piovesan Pereira B., Wang X., Tagkopoulos I. Biocide-induced emergence of antibiotic resistance in Escherichia coli. Front. Microbiol. 2021;12:640923. DOI: https://doi.org/10.3389/fmicb.2021.640923</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Barakat N.A., Rasmy S.A., Hosny A.E., Kashef M.T. Effect of povidone-iodine and propanol-based mecetronium ethyl sulphate on antimicrobial resistance and virulence in Staphylococcus aureus. Antimicrob. Resist. Infect. Control. 2022;11(1):139. DOI: https://doi.org/10.1186/s13756-022-01178-9</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Циркунова Ж.Ф., Емельянова А.А., Гудкова Е.И. и др. Влияние субингибирующих концентраций биоцидов на формирование адаптивной устойчивости клинических изолятов Klebsiella pneumoniae. Иммунопатология, аллергология, инфектология. 2022;(3):31–40. Tsirkunova Zh.F., Emel'yanova A.A., Gudkova E.I., et al. Effect of subinhibitory concentrations of biocides on formation of adaptive resistance of clinical isolates of Klebsiella pneumoniae. Immunopathology, Allergology, Infectology. 2022;(3):31–40. DOI: https://doi.org/10.14427/jipai.2022.3.30 EDN: https://www.elibrary.ru/ngcexg</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Jutkina J., Marathe N.P., Flach C.F., Larsson D.G.J. Antibiotics and common antibacterial biocides stimulate horizontal transfer of resistance at low concentrations. Sci. Total Environ. 2018;616-617:172–8. DOI: https://doi.org/10.1016/j.scitotenv.2017.10.312</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Fraud S., Campigotto A.J., Chen Z., Poole K. MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor. Antimicrob. Agents Chemother. 2008;52(12):4478–82. DOI: https://doi.org/10.1128/AAC.01072-08</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Di Cesare A., Fontaneto D., Doppelbauer J., Corno G. Fitness and recovery of bacterial communities and antibiotic resistance genes in urban wastewaters exposed to classical disinfection treatments. Environ. Sci. Technol. 2016;50(18):10153-61. DOI: https://doi.org/10.1021/acs.est.6b02268</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Mavrommatia M., Daskalakia A., Papanikolaou S., Aggelis G. Adaptive laboratory evolution principles and applications in industrial biotechnology. Biotechnol. Advances. 2022;54:107795. DOI: https://doi.org/10.1016/j.biotechadv.2021.107795</mixed-citation></ref></ref-list></back></article>
